COMP <GO>
CORT vs TGTX // REVENUE GROWTH (YOY)
Corcept Therapeutics Incorporated (NASDAQ) VS. TG Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CORT 5
— TGTX 8
▲ REVENUE GROWTH (YOY) LEADER: TGTX
LAST: $80.46 (-0.81%) • MKT CAP: $8.70B
revenue-growth
12.80%
LAST: $59.95 (-2.01%) • MKT CAP: $9.18B
revenue-growth
87.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CORT VS. TGTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CORT | TGTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 83.70% | +12.30 | CORT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.80% | 12.00% | -7.20 | TGTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 73.3x | +21.70 | TGTX | /valuation <GO> |
| Free Cash Flow Yield | 1.53% | -0.28% | +1.81 | CORT | /fcf-yield <GO> |
| Operating Margin | 5.90% | 20.00% | -14.10 | TGTX | /operating-margins <GO> |
| Net Profit Margin | 13.10% | 68.00% | -54.90 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 12.80% | 87.30% | -74.50 | TGTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 12.92 | +13.08 | CORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | CORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.2 | 60.3 | -33.10 | TGTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.87 | +0.01 | CORT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 78.3x | 16.7x | +61.60 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.70B | $9.18B | -$478.9M | TGTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CORT REV | TGTX REV | CORT GROSS % | TGTX GROSS % | CORT FCF | TGTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $761.4M | $616.3M | 98.3% | 83.7% | $141.8M | -$25.0M |
| FY 2024 | $675.0M | $329.0M | 98.4% | 88.3% | $196.1M | -$40.6M |
| FY 2023 | $482.4M | $233.7M | — | — | $105.0M | -$41.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CORT // BETA 0.88
TGTX // BETA 0.87